Sichuan Kelun Pharmaceutical (002422) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 was ¥4.26 billion, down 2.98% year-over-year.

• Net profit attributable to shareholders was ¥453.7 million, a 22.34% decrease year-over-year.

• Cash flow from operating activities dropped 44.45% year-over-year to ¥249.6 million.

• Significant R&D investments and new product developments were highlighted.

Financial highlights

• Operating income: ¥4.26 billion, down from ¥4.39 billion year-over-year.

• Net profit: ¥453.7 million, down from ¥584.2 million year-over-year.

• Basic and diluted EPS: ¥0.29, down from ¥0.37 year-over-year.

• Total assets at quarter-end: ¥41.14 billion, up 3.28% from year-end 2025.

• Owner's equity: ¥24.64 billion, up 1.71% from year-end 2025.

Outlook and guidance

• Multiple new drug clinical trials and product approvals signal ongoing innovation.

• Continued focus on R&D and product pipeline expansion.